Predicting Opportunity in Emerging Therapies
The emergence of novel therapies, particularly in the metabolic space, presents valuable opportunities for drug manufacturers, who have strategically invested in these areas. However, accurately sizing these nascent markets, often characterized by well-documented unmet clinical needs, poses unique challenges.
In our latest paper, we explore these challenges using the glucagon-like peptide-1 (GLP-1) market as a prime example. It highlights the importance of a comprehensive approach to market sizing, moving beyond epidemiological data to incorporate prescription rates, access considerations, stakeholder perceptions, and real-world treatment data.
The paper provides valuable guidance for navigating these complex markets, emphasizing the need for robust primary market research, expert consultation, and a deep understanding of stakeholder perceptions. By addressing potential pitfalls and offering practical strategies, this paper equips manufacturers with the tools to confidently evaluate opportunities and make informed decisions in these evolving therapeutic areas.
Ipsos’ GLP-1 Market Sizing Study, which gauges caseload and GLP-1 volume usage across a variety of clinician stakeholders, will be available in Q4 ’24.
